Company to focus on pipeline of Pentarins™ as a unique and promising approach to treating solid tumor cancers Lead drug candidate PEN-221 targeting neuroendocrine and small cell lung cancers to […]
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Business Wirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBusiness Wire2016-01-27 07:00:002016-01-27 12:35:03Blend Therapeutics Secures $38 Million in Series C Financing led by Novo A/S and NEA and Changes Name to Tarveda Therapeutics